Evidence Updates
AF Follow-Up: Rhythm Improvement and Stroke Prevention Are Different Decisions
Editorial record
This source-linked educational article has been updated through AI-assisted evidence checks and editorial review. Verify information against current guidance and local protocols before applying it to patient care.
Citation methodologyA patient feels well after rhythm treatment and asks whether the anticoagulant is still needed. That is not answered by the symptom score or a single tracing showing sinus rhythm. Follow-up needs to revisit thromboembolic risk, bleeding concerns, treatment effects, and the patient's priorities separately.
A Risk Score Does Not Disappear With Symptoms
Consider a fictional 71-year-old man with hypertension and diabetes and no other score components. Age 65-74 contributes one point, hypertension one, and diabetes one: CHA2DS2-VASc = 3. The corresponding CHA2DS2-VA total is also three. Successful symptom control does not erase these risk factors.
The 2024 ESC framework recommends basing ongoing anticoagulation on individual thromboembolic risk rather than simply whether the patient currently appears to be in AF or sinus rhythm. This is a guideline-based framework, not a claim that every patient must receive the same drug indefinitely. Post-ablation decisions and changing bleeding risk require individualized specialist review; patients should not stop anticoagulation solely because they feel better. ESC 2024 essential messages.
The companion stroke-risk score guide explains the difference between US CHA2DS2-VASc and ESC CHA2DS2-VA thresholds. This page addresses what happens after treatment starts.
What Newer Post-Ablation Trials Add
The 2024 guideline predates two important randomized reports. ALONE-AF enrolled 840 adults in South Korea without documented atrial arrhythmia recurrence for at least a year after ablation. Stopping anticoagulation reduced its two-year composite of stroke, systemic embolism, or major bleeding, largely through fewer major bleeds. Only nine primary events occurred; this does not establish safety for every high-risk patient. Rhythm surveillance and reassessment were part of the trial. ALONE-AF primary report.
OCEAN compared rivaroxaban with aspirin in 1,284 selected patients at least a year after successful ablation. It did not demonstrate a statistically significant reduction in its composite embolic outcome with rivaroxaban. Few events and a wide confidence interval do not prove equivalence, and aspirin was an active comparator, not no treatment. These trials inform specialist shared decisions; they do not justify stopping an anticoagulant or substituting aspirin solely because symptoms have resolved. OCEAN primary report.
What Early Rhythm Control Actually Showed
EAST-AFNET 4 randomized 2,789 patients with AF diagnosed within the preceding year and cardiovascular conditions to early rhythm control or usual care. Its primary efficacy outcome combined cardiovascular death, stroke, and hospitalization for worsening heart failure or acute coronary syndrome. Rates were 3.9 versus 5.0 events per 100 person-years, with a hazard ratio of 0.79. This supports a strategy in a defined trial population; it does not prove that every component improved independently or that every patient should undergo ablation. Serious adverse events related to rhythm-control treatment were reported in 4.9% versus 1.4%. EAST-AFNET 4 primary report.
The simple difference, 5.0 - 3.9 = 1.1 events per 100 person-years, is a rate difference, not a patient-specific benefit or a fixed-time number needed to treat. Discuss potential benefit alongside adverse effects and the patient's treatment options.
Registry Associations Are Not Prescribing Guarantees
The AF-GEN-UK registry reported associations between anticoagulation and lower mortality and stroke in participants with CHA2DS2-VASc at least two. Its adjusted hazard ratios of 0.48 and 0.11 correspond arithmetically to 52% and 89% lower hazards. Those are observational associations, not randomized proof of those exact benefits for every score category. Confounding and treatment selection remain relevant. AF-GEN-UK registry report.
Make the Follow-Up Specific
Review whether symptoms or functional capacity improved, whether AF has recurred, and whether treatment has caused problems. Reassess evolving stroke and bleeding risks, medication adherence, and factors that affect drug choice or dose. A recurrence plan and a stroke-prevention plan should be documented separately. The current ESC guideline organizes care around comorbidity management, stroke prevention, symptom reduction, and repeated evaluation. ESC AF guideline.
The practical question is not "Did treatment make the score unnecessary?" It is "Which risks changed, which did not, and what needs to be reconsidered together?"